Generic Drug Manufacturing Plant Project Report- One of the Biggest Market Drivers is an Increasing Global Pharmaceutical Spending Trend Towards Generics. By a News Reporter-Staff News Editor at Investment Weekly News Research and Markets has announced the addition of the "Generic Drug Manufacturing Plant Project Report: Industry Trends, Manufact
Perrigo Co. plc is intending to purchase a drug from pharmaceutical maker AstraZeneca to treat Crohn s disease. The deal for the gastroenterology drug Entocort and its generic capsule version will be worth $380 million and is expected to close by the end of the year. According to Chairman and CEO Joe Papa, the drug goes well with Perrigo s current
BASEL- Amgen has submitted its Biologics License Application with the FDA for ABP 501, a biosimilar candidate to AbbVie's Humira. The filing represents Amgen's first BLA submission using the 351 biosimilar pathway. While biosimilar products have been available in Europe since 2006, it was only very recently did the FDA give green light to the first
When William Comanor was casting about for a thesis in the fall of 1961 to complete his Ph.D. in economics at Harvard University, a professor suggested he look into the pharmaceutical industry. Congress, at the time, had been holding hearings on drug manufacturers for more than a year. His landmark paper a year later, "Research and Competitive Prod
Lannett Company, Inc. today announced that it has completed the acquisition of Kremers Urban Pharmaceuticals Inc., the U.S. specialty generic pharmaceuticals subsidiary of global biopharmaceuticals company UCB S.A.. Lannett has acquired KU from UCB for total consideration of approximately US $1.23 billion, subject to certain adjustments, includin
KUALA LUMPUR: The chances of extended patent protection for drugs in Malaysia is very small, said Malaysia's chief negotiator in the Trans-Pacific Partnership negotiations Datuk J. Jayasiri. "We are going to set up a soft linkage between the patent office and drug authority, so that whenever a generic manufacturer seeks a marketing approval, the d
THOUSAND OAKS- Amgen announced the submission of a Biologics License Application or BLA with the United States Food and Drug Administration for ABP 501, a biosimilar candidate to Humira or adalimumab. Amgen believes this submission is the first adalimumab biosimilar application submitted to the FDA and represents Amgen's first BLA submission using
Summary DelveInsight's, "Biosimilar- Competitive Landscape and Market& Pipeline Analysis, 2015" discusses the global insulin biosimilar industry. Report analyzes that Insulin and Insulin Biosimilars holds a future scope and potential in the market. It provides detailed information on the 11 Insulin Biosimilar that are in pipeline. It analyses Ins
Lannett Co. might be a takeover target or a buyer in the future, but now it is trying to digest a complicated acquisition of its own from September and a smaller one from May. Lannett, with 502 employees and five Philadelphia properties, was formed by two pharmacist brothers in 1942, before there was a distinct generic-drug industry. Today, with on
Analysis from business intelligence provider GBI Research- Life Cycle Management Strategies- Optimizing revenues and defending generic competition- says that it is becoming increasingly important for pharmaceutical companies to implement suitable life cycle management strategies in order to maximize revenues and the lifespan of their portfolios..
The changing landscape of the U.S. health care system has resulted in rising costs for prescription medications, causing a real health and financial burden for many Americans. According to the Generic Pharmaceutical Association, generic medications can cost 30 to 80 percent less than their brand-name counterparts. In 2014, the FamilyWize Prescrip
Allergan plc, a leading global pharmaceutical company, and Rugen Therapeutics, a start-up biotechnology company focused on the development of novel treatments for unmet CNS disorders and funded by the F-Prime Biomedical Research Initiative, today announced that they have entered into an exclusive collaboration to support the discovery and develop
Amgen today announced the submission of a Biologics License Application with the United States Food and Drug Administration for ABP 501, a biosimilar candidate to Humira . Amgen believes this submission is the first adalimumab biosimilar application submitted to the FDA and represents Amgen's first BLA submission using the 351 biosimilar pathwa
-Amphastar Pharmaceuticals, Inc. announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at the 27th Annual Piper Jaffray Healthcare Conference on Tuesday, December 1, 2015 at 11:30 a.m. Eastern Standard Time in New York, NY. This press release contains forward-looking statements, including statements relating to Amph
Deal Type: Venture Financing Deal Sub Type: Start Up Deal Country: United States of America Deal Status: Announced Deal Value: 7.0000 USD. Appco Pharma LLC, a generic pharmaceutical company, has announced to raise USD3 million in venture financing round. Index- Drug Manufacturing Index- Generics Index- API Manufacturers Index- United States of Amer
This determination will allow FDA to approve abbreviated new drug applications for TYLENOL WITH CODEINE oral tablets, 325 mg/7. 5 mg, 325 mg/15 mg, 325 mg/30 mg, and 325 mg/60 mg, if all other legal and regulatory requirements are met. The 1984 amendments include what is now section 505 of the Federal Food, Drug, and Cosmetic Act, which requires FD
Lannett Co. Inc. might be a takeover target or a buyer in the future, but it is now trying to digest a complicated acquisition of its own from September and a smaller one from May. Lannett, with 502 employees and five Philadelphia properties, was formed by two pharmacist brothers in 1942, before there was a distinct generic-drug industry. Today, wi
Impax Laboratories, Inc. today announced that the European Commission has granted marketing authorization for NUMIENT, a modified-release oral capsule formulation for the symptomatic treatment of adult patients with Parkinson's disease. The review of this application was conducted under the centralized licensing procedure as a therapeutic...
-Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Company is scheduled to present at the LD Micro Main Event on December 2, 2015. The presentation may be accessed..
Attorney General Eric Schneiderman and Allergan PLC said Wednesday that they have agreed to resolve the lawsuit filed over the company's plans to withdraw Namenda, a popular Alzheimer's treatment, a few months before lower-cost generic drugs became available. A federal judge agreed last year, requiring Allergan to continue distributing the older dr
Developmental, commercial, and regulatory/legal strategies all play a key role in boosting the profitability of pharmaceutical products, says GBI Research.. Analysis from business intelligence provider GBI Research- Life Cycle Management Strategies- Optimizing revenues and defending generic competition- says that it is becoming increasingly...
By a News Reporter-Staff News Editor at Telecommunications Weekly Teligent, Inc., a New Jersey- based specialty generic pharmaceutical company, announced it has completed the acquisition of the assets of Alveda Pharmaceuticals, Inc. for $47 million CAD in cash. Announced in October 2015, the accretive transaction provides Teligent a platform to e